Ethosuximide : List of nationally authorised medicinal products - PSUSA/00001316/202303
Human medicines European public assessment report (EPAR): Simulect, basiliximab, Graft Rejection;Kidney Transplantation, Date of authorisation: 09/10/1998, Revision: 28, Status: Authorised
Seventh Industry Standing Group (ISG) meeting, European Medicines Agency, Amsterdam, the Netherlands, from 23/11/2023 to 23/11/2023
Human medicines European public assessment report (EPAR): Byfavo, remimazolam, Conscious Sedation, Date of authorisation: 26/03/2021, Revision: 6, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Sirolimus, decision type: , therapeutic area: , PIP number: P/0480/2022
Opinion/decision on a Paediatric investigation plan (PIP): 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1 (pridopidine hydrochloride), decision type: , therapeutic area: , PIP number: P/0546/2022
Reflection paper on ethical and good-clinical-practice aspects of clinical trials of medicinal products for human use conducted outside of the European Union (EU) / European Economic Area and submitted in marketing-autho...
Opinion/decision on a Paediatric investigation plan (PIP): exanatide, decision type: , therapeutic area: , PIP number: P/0475/2022
European experts
Opinion/decision on a Paediatric investigation plan (PIP): cobolimab, decision type: , therapeutic area: , PIP number: P/0512/2022